Bacillus anthracis cell wall

The Bacillus anthracis cell wall is a complex, multi-layered envelope that is vital for the bacterium's structural integrity, growth, and pathogenicity. It consists of a thick peptidoglycan layer that provides mechanical strength and protects the cell from osmotic lysis (Missiakas & Schneewind, 2013). This layer is uniquely modified with secondary cell wall polysaccharides (SCWP), which are essential for anchoring surface-layer (S-layer) proteins and the poly-D-glutamic acid capsule to the cell surface (Journal of Biological Chemistry, 2005). These surface components allow the pathogen to evade host immune responses and persist in harsh environments. In clinical practice, the cell wall is a primary target for antibiotics such as penicillins and glycopeptides, which disrupt peptidoglycan synthesis and lead to bacterial death (CDC, 2022). However, the effectiveness of these treatments can be compromised by the bacterium's endogenous beta-lactamases and the risk of toxin release during rapid cell lysis (StatPearls, 2023). Consequently, the cell wall remains a focal point for both diagnostic development and the engineering of next-generation antimicrobial therapies.

Other names

Anthrax cell wallB. anthracis peptidoglycan layerBacillus anthracis cell envelope

Drugs targeting the Bacillus anthracis cell wall primarily act by inhibiting the synthesis or cross-linking of the peptidoglycan layer. Beta-lactam antibiotics bind to and inhibit penicillin-binding proteins (PBPs), which are transpeptidases essential for forming the cross-links that stabilize the cell wall (StatPearls, 2023). Glycopeptides like vancomycin bind to the D-alanyl-D-alanine terminus of cell wall precursors, sterically hindering the addition of new subunits to the peptidoglycan chain (CDC, 2022).